Allergan Cuts Deal With Generic Cos. Over Depression Drug

By Andrew Karpan (September 15, 2021, 8:40 PM EDT) -- A New Jersey federal judge has signed off on a deal between Allergan and two generic-drug makers to resolve patent infringement suits it launched to prevent a generic version of its depression drug Fetzima from hitting the market.

In a pair of five-page orders handed down Tuesday, U.S. District Judge Esther Salas agreed to the terms of two stipulations that AbbVie unit Allergan inked with MSN Laboratories and Aurobindo Pharma, the only generic-drug makers left from a raft of abbreviated new drug application lawsuits Allergan unit Forest Laboratories filed in New Jersey federal court in 2017.

By the terms of the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!